BioTuesdays

Author - Sydney Stewart

SVB Leerink starts Immunic at OP, PT $45

SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1. Immunic is focused on development of novel therapeutics for the treatment of...

Selecta Biosciences

William Blair cuts Selecta Biosciences to MP

William Blair downgraded Selecta Biosciences (NASDAQ:SELB) to “market perform” after the company and partner, Swedish Orphan Biovitrum, announced top-line data from the Phase 2 COMPARE trial, comparing Selecta’s SEL-212...

AGP starts Trulieve Cannabis at buy; PT $40 (Canadian)

Alliance Global Partners launched coverage of Trulieve Cannabis (CSE:TRUL) with a “buy” rating and $40 (Canadian) price target. The stock was quoted at $23.74 in afternoon trading on Sept. 25. “We view Trulieve as a...

Maxim starts Monopar Therapeutics at buy; PT $11

Maxim Group launched coverage of Monopar Therapeutics (NASDAQ:MNPR) with a “buy” rating and a 12-month price target of $11. The stock closed at $4.98 on Sept. 24. Monopar is focused on developing therapies for cancer...

BTIG starts MediWound at buy; PT $6

BTIG initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $6 price target. The stock closed at $3.58 on Sept. 22. MediWound has developed proteolytic enzyme technology targeting severe burns, chronic...

DermTech-Logo

Cowen starts DermTech at OP; PT $20

Cowen launched coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating and $20 price target. The stock closed at $10.65 on Sept. 9. DermTech provides the only commercial-stage genomics-based non-invasive solution...